MilsteinC: The hybridoma revolution: An offshoot of basic research. Bioessays, 1999; 21:966–973.
2.
KöhlerG: Why hybridomas?. Hybridoma, 1981; 1:1–4.
3.
DattaD, KunduPK, BiswasS, DasguptaS, BhingeA, ChandranV: Effect of cationic amino acid, L-lysine and its polymers on the growth and secretion of hybridoma cell line OKT-3. Hybridoma, 2000; 19:339–346.
4.
FoxFE, ChernajovskyY, PlatsoucasCD: Inhibition of interleukin 2 production and alteration of interleukin 2 mRNA processing by human T-T cell hybridoma-derived suppressor factors. Hybridoma, 1994; 13:343–352.
5.
WangCY, BushkinY, PicaR, LaneC, McGrathH, PosnettDN: Stimulation and expansion of a human T-cell subpopulation by a monoclonal antibody to T-cell receptor molecule. Hybridoma, 1986; 5:179–190.
6.
HsuSM, ZhangHZ, JaffeES: Monoclonal antibodies directed against human lymphoid, monocytic, and granulocytic cells: Reactivities with other tissues. Hybridoma, 1983; 2:403–412.
7.
SyrigosKN, PliarchopoulouK, HarringtonKJ: The development of monoclonal antibody therapy in leukemias. Hybridoma, 2001; 20:145–148.
8.
WangM, ZhangW, ZhangY: Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Hybridoma (Larchmt), 2009; 28:333–339.
9.
ChenY, HuZ, WangQ, GeY, BaiL, WangX, ZhangX: Generation and characterization of four novel monoclonal antibodies against human programmed death-1 molecule. Hybridoma (Larchmt), 2010; 29:153–160.
10.
QinYE, WangG, YangJ, LiuCQ: Generation of a monoclonal antibody recognizing mouse PD-1. Monoclon Antib Immunodiagn Immunother, 2014; 33:361–364.
11.
RitprajakP, HashiguchiM, AkibaH, YagitaH, OkumuraK, AzumaM: Antibodies against B7-DC with differential binding properties exert opposite effects. Hybridoma (Larchmt), 2012; 31:40–47.
12.
AlirezapourB, RajabibazlM, RasaeeMJ, OmidfarK: Production and characterization of recombinant scFv against digoxin by phage display technology. Monoclon Antib Immunodiagn Immunother, 2013; 32:172–179.
13.
MohammadiM, RasaeeMJ, RajabibazlM, PaknejadM, ZareM, MohammadzadehS: Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques. Hybridoma (Larchmt), 2007; 26:223–230.
14.
MohammadzadehS, RajabibazlM, FourozandehM, RasaeeMJ, RahbarizadehF, MohammadiM: Production of recombinant scFv against p24 of human immunodeficiency virus type 1 by phage display technology. Monoclon Antib Immunodiagn Immunother, 2014; 33:28–33.
15.
SchlebuschH, ReinartzS, KaiserR, GrünnU, WagnerU: Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique. Hybridoma, 1997; 16:47–52.
16.
ShuiX, HuangJ, LiYH, XiePL, LiGC: Construction and selection of human Fab antibody phage display library of liver cancer. Hybridoma (Larchmt), 2009; 28:341–347.
17.
SrivastavaN, ZeilerJL, SmithsonSL, CarloneGM, AdesEW, SampsonJS, JohnsonSE, Kieber-EmmonsT, WesterinkMA: Selection of an immunogenic and protective epitope of the PsaA protein of Streptococcus pneumoniae using a phage display library. Hybridoma, 2000; 19:23–31.
18.
Abdolahi KhabisiS, SarkariB, MoshfeA, JalaliS: Production of monoclonal antibody against excretory-secretory antigen of fasciola hepatica and evaluation of its efficacy in the diagnosis of fascioliasis. Monoclon Antib Immunodiagn Immunother, 2017; 36:8–14.
19.
KarimiMH, EbadiP, PourfathollahAA, MoazzeniM, SoheiliZS, SamieeS: Comparison of three techniques for generation of tolerogenic dendritic cells: siRNA, oligonucleotide antisense, and antibody blocking. Hybridoma (Larchmt), 2010; 29:473–480.
20.
Kuus-ReichelK, KnottCL, Sam-FongP, JueRA, MackensenDG, CorvalanJR: Production and in vivo characterization of a bifunctional antibody (IVA039.1) with specificity for the mouse interleukin-2 receptor and vinca alkaloids. Hybridoma, 1994; 13:115–122.
21.
ShenD, TangY, LiS, XuW, ZhangL: Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b. Monoclon Antib Immunodiagn Immunother, 2014; 33:215–220.
22.
StaquetK, Giles-KomarJ: A rapid and efficient in vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of cancer. Hybridoma (Larchmt), 2006; 25:68–74.
23.
SyrigosKN, DeonarianDP, EpenetosAA: Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. Hybridoma, 1999; 18:219–224.
24.
SyrigosKN, EpenetosAA: Radioimmunotherapy of ovarian cancer. Hybridoma, 1995; 14:121–124.
25.
ChongSL, MouDG, AliAM, LimSH, TeyBT: Cell growth, cell-cycle progress, and antibody production in hybridoma cells cultivated under mild hypothermic conditions. Hybridoma (Larchmt), 2008; 27:107–111.
26.
GolestaniR, PourfathollahAA, MoazzeniSM: An extreme strategy for the production of hybridoma. Hybridoma (Larchmt), 2009; 28:139–144.
27.
HnaskoR, LinAV, StankerL, McGarveyJ: A bioassay for optimization of macrophage-conditioned medium as a culture supplement to promote hybridoma cell survival and growth. Monoclon Antib Immunodiagn Immunother, 2018; 37:126–133.
28.
MalaeiF, RasaeeMJ, PaknejadM, LatifiAM, RahbarizadehF: Production and characterization of monoclonal and polyclonal antibodies against truncated recombinant Dickkopf-1 as a candidate biomarker. Monoclon Antib Immunodiagn Immunother, 2018; 37:257–264.
29.
NalbantsoyA, BoraK, Deliloglu-GurhanI: Metabolic activity and monoclonal antibody production of Salmonella enteritidis O and H antigen specific hybridoma cells in static culture. Hybridoma (Larchmt), 2011; 30:189–193.
